Loette Contraindications

Loette 21 must not be used in women with any of the following conditions: Deep vein thrombosis (current or history).
Thromboembolism (current or history).
Cerebrovascular or coronary artery disease.
Thrombogenic valvulopathies.
Thrombogenic rhythm disorders.
Hereditary or acquired thrombophilias.
Headache with focal neurological symptoms, such as aura.
Diabetes with vascular involvement.
Uncontrolled hypertension.
Known or suspected carcinoma of the breast, or other known or suspected estrogen dependent neoplasia.
Hepatic adenomas or carcinomas, or active liver disease, as long as liver function has not returned to normal.
Undiagnosed vaginal bleeding.
Pancreatitis associated with severe hypertriglyceridemia (current or history).
Known or suspected pregnancy.
Hypersensitivity to any of the components of Loette 21.
Disorders of lipometabolism.
Sickle cell anemia.
Loette 21 is contraindicated for concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir (see Warnings and Interactions).
Reasons for the immediate discontinuation of Loette 21: Occurrence for the first time of migrainous headaches or the more frequent occurrence of unusually severe headaches.
Acute disturbances of vision, hearing, or speech.
First symptoms of thrombophlebitis or thromboembolism (e.g., unusual pain in or swelling of the legs, stabbing pain on breathing, or coughing for no apparent reason).
Feeling of pain or tightness in the chest.
Six weeks before planned operations or during prolonged periods of immobilization.
Development of jaundice (cholestasis), hepatitis, or generalized pruritus.
Increase in epileptic seizures.
Significant rise in blood pressure.
Onset of severe clinical depression.
Severe upper abdominal pain or liver enlargement.
Pregnancy.